Status:

TERMINATED

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Lead Sponsor:

Akros Pharma Inc.

Conditions:

Plaque Psoriasis

Skin Diseases

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.

Eligibility Criteria

Inclusion

  • Diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1
  • Plaque-type psoriasis covering ≥10% of body surface area (BSA) at Visit 1 and Visit 2;
  • Psoriasis Area and Severity Index (PASI) score ≥12 at Visit 1 and Visit 2;
  • Static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2;
  • Body Mass Index (BMI) ≤40 at Visit 1.

Exclusion

  • Medical history of treatment failure to any systemic agents for plaque psoriasis;
  • Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions at (e.g., clinically-significant eczema or severe acne) that could interfere with study evaluations at Visit 1;
  • Presence or history of any itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin (e.g., drug induced pruritus, significant other systemic diseases with itch) within 12 months prior to Visit 1;
  • History of a clinically-significant infection (e.g., that required oral antimicrobial therapy) within 8 weeks prior to Visit 2;
  • History of infections requiring hospitalization or parenteral antibiotic, antiviral, antifungal or antiparasitic therapy within 6 months prior to Visit 2 and no history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis);

Key Trial Info

Start Date :

November 10 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 29 2018

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT03358290

Start Date

November 10 2017

End Date

October 29 2018

Last Update

August 6 2021

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

First OC Dermatology

Fountain Valley, California, United States, 92708

2

Center For Dermatology Clinical Research, Inc.

Fremont, California, United States, 94538

3

University of South Florida - Hospital

Tampa, Florida, United States, 33612

4

Atlanta Dermatology Vein and Research Center LLC

Alpharetta, Georgia, United States, 30022